Missouri medicineOct 17, 2026

Metabolic Surgery Compared to Glucagon-Like Peptide-1 Drugs for Treating Obesity and Related Health Problems

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 19, 2026

Abstract

Bariatric surgery remains a gold-standard treatment for obesity, even as glucagon-like peptide one receptor agonists emerge as effective non-surgical options.

Obesity is increasingly recognized as a chronic disease with rising prevalence.
Bariatric surgery has been an effective treatment for obesity and related diseases for decades.
Newer glucagon-like peptide one receptor agonists represent the most effective non-surgical therapy to date.
Debate exists regarding the comparative effectiveness of surgical versus non-surgical therapies for obesity.
Consideration is needed for both monotherapy and combination therapy in treating chronic obesity.

Simplified

Obesity as a chronic disease continues to increase in prevalence despite continual advancements in surgical and medical therapy. Bariatric surgery has been the gold-standard for effective treatment of obesity and its related diseases for multiple decades. However, with the continual introduction of newer and more effective glucagon-like peptide one receptor agonists, the most effective non-surgical therapy to date, the debate has begun about which therapy is more effective in treating patients suffering from chronic obesity. As data continues to emerge, further consideration must be given regarding the use of these modalities as monotherapy or as combination therapy for treating obesity. We will provide arguments for each therapy and make a further argument for multimodal therapy to treat the challenging disease of obesity.

Metabolic Surgery Compared to Glucagon-Like Peptide-1 Drugs for Treating Obesity and Related Health Problems

Abstract

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief